PHAXIAM Therapeutics
Vaishali Mistry is a Quality Assurance Specialist at ERYTECH Pharma since May 2021, bringing expertise in quality assurance processes. Prior to this role, Vaishali served as a Production Specialist at Akorn, Inc. from October 2020 to April 2021. Vaishali's earlier experience includes working as a Quality Associate at PharMEDium Services, Amerisource Bergen from August 2016 to April 2020, where foundational skills in quality systems were developed.
This person is not in any offices
PHAXIAM Therapeutics
PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.